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Objective: Since statins and ﬁbrates are capable of improving the metabolic proﬁle of patients as well as
decreasing inﬂammation, they are considered as potential drugs for preventing osteoarthritis (OA). The
goal of the present study was to investigate the effect of these drugs in the STR/Ort spontaneous OA
mouse model.
Design: Male STR/Ort mice received control diet or control diet containing two different dosages of
simvastatin or fenoﬁbrate or a combination of both. Mice were euthanized after 16 weeks of treatment at
the age of 24 weeks. Serum analysis for metabolic and inﬂammatory markers, histologic OA grading and
micro computed tomography (mCT) analysis of subchondral bone plate were performed.
Results: Simvastatin treatment did not have a statistically signiﬁcant effect on any of the measured
parameters. Fenoﬁbrate treated mice gained less body weight (BW) and had lower serum amyloid A
(SAA) levels, but higher Interleukin (IL)-1a and MIP1a than other mice. Mice treated with 200 mg/kg BW/
day fenoﬁbrate had less subchondral bone plate volume than control, but no statistically signiﬁcant
reduction in cartilage damage. In the combination treatment group, BW and SAA were lower than
control.
Overall, bodyweight, synovium membrane cell layers and SAA levels correlated to subchondral bone
plate changes and subchondral bone plate changes correlated to cartilage damage.
Conclusions: Statins and ﬁbrates did not affect development of cartilage damage in the STR/Ort spon-
taneous OA mouse model. Fenoﬁbrates however, had an effect on BW, serum inﬂammation markers and
subchondral bone plate morphology.
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The current non surgical treatment options for osteoarthritis
(OA) are limited to non pharmacological interventions such as life
style changes, exercise or weight reduction, with pharmacological
treatment of symptoms if needed. No effective disease modifying
drug is currently on the market for OA1. OA is a common joint
disease that affects the entire joint, including the articular cartilage,
subchondral bone and the synovial membrane. High age and
obesity are both major risk factors of OA. Prevalence and incidenceublished by Elsevier Ltd. All rights reserved.
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growing obesity2,3.
The metabolic syndrome is a concurrence of obesity, hyper-
insulinemia, dyslipidemia and hypertension4. Metabolic OA is
considered one of the subtypes of OA and is associated with the
metabolic syndrome. Besides hyperglycaemia and increased serum
lipids, also the vascular pathology associated with the metabolic
syndrome might have negative effects on the cartilage5.
Statins are hydroxylmethylglutaryl coenzyme-A reductase in-
hibitors that decrease serum cholesterol levels, reduce systemic
inﬂammation, and decrease the amount of cardiovascular events6,7.
Fibrates are ligands of Peroxisome Proliferator Activated Receptor
(PPAR)a. These drugs decrease serum triglycerides and also exert
anti-inﬂammatory effects on different tissues. Like statins, they
decrease inﬂammatory processes in cartilage, synovium and intra-
articular adipose tissue in in vitro studies8e14. Chronic low grade
inﬂammation plays an important role in the pathogenesis of OA and
metabolic syndrome4. Since statins and ﬁbrates can potentially
inhibit inﬂammatory processes in the joint as well as improve the
metabolic proﬁle of patients, they might offer a potential thera-
peutic or preventive strategy for OA. Recently, we associated the
use of statins with decreased incidence and slower progression of
knee OA in the Rotterdam Study on X-rays15. Kadam et al. associated
the use of statin with decreased incidence of clinical OA in the
General Practice Research Database from the United Kingdoms16.
No direct association between the use of ﬁbrates and incidence of
OA has been described yet17. Before starting a clinical trial that
directly addresses the question whether statins and ﬁbrates are
able to prevent OA or OA progression, an in vivo animal study
should be performed.
In the STR/Ort mouse strain, 80% of the male mice spontane-
ously develop OA in the tibiofemoral joint at the age of 6 month,
particularly at the medial condyles with similar histopathological
lesions as in humans18. STR/Ort mice also spontaneously develop
obesity19. Furthermore, serum levels of total cholesterol, high
density lipoprotein (HDL) cholesterol, LDL cholesterol, triglycerides,
nonesteriﬁed fatty acids, glucose and insulin are reported to be
increased in STR/Ort mice compared to C57BL/6J mice19. In addition
it has been suggested that STR/Ort mice develop OA spontaneously
due to the reduction of endogenous PPARa or PPARg signalling, and
thus possibly increasing inﬂammation and altering osteoblast
phenotype20.
For these reasons, the STR/Ort mouse model seems eminently
suited to investigate the effects of statins and ﬁbrates on OA
development. In this study, we investigated whether administra-
tion of simvastatin or fenoﬁbrate or a combination of both would
prevent or delay the development of OA in the tibiofemoral joint.
We evaluated the effect of this treatment on serum cholesterol,
triglyceride, the inﬂammation marker serum Amyloid A (SAA) and
the inﬂammatory cytokines in the blood. Cartilage damage was
evaluated with histology and joint bone morphology with micro
computed tomography (mCT).
Method
Animals
Four-week-old male STR/Ortmice (n¼ 72) acquired fromHarlan
Italy (Udine, Italy) were maintained at the animal testing facilities
of the Erasmus MC University Medical Center, The Netherlands.
Mice were housed in groups of three mice per cage under standard
conditions and had access to water and food ad libitum. The study
protocol was approved by the institutional Animal Care and Use
Committee (Erasmus MC University Medical Center, The
Netherlands, AEC 116-10-01).Diets and drug intake
Micewere fed semi-synthetic non-irradiatedmice reference diet
(AbDiets,Woerden, The Netherlands) for 4 weeks before feeding the
experimental diets. Bodyweight (BW) wasmeasured every 2 weeks
and foodwas replaced two to three times per week. Average BWper
mouse and average food intake per cage per day could thus be
determined and we could calculate the amount of drugs (mg/kg)
needed to be mixed with reference diet for the mice to receive the
intended target dosage (mg/kg BW/day). At the age of 8 weeks, the
mice were divided into six experimental groups of n ¼ 12. Group 1
(control) continued to receive the non-supplemented reference
diet. Group 2 and 3 received reference diet mixedwith either 300 or
750 mg/kg simvastatin (Eurogenerics, Brussel, Belgium), which
corresponds to dosages of 40 and 100 mg/kg BW/day. Groups 4 and
5 received reference diet mixed with either 600 or 1500 mg/kg
fenoﬁbrate (Eurogenerics, Brussel, Belgium), which corresponds to
dosages of 80 and 200 mg/kg BW/day. Finally, group 6 received a
combination of simvastatin (300 mg/kg) and fenoﬁbrate (600 mg/
kg) with dosages 40 and 80 mg/kg BW/day respectively. Target
dosages of each drug were based upon what is often used in the
literature to study the anti-inﬂammatory or lipid lowering effects of
these drugs21. All experimental diets were provided and mixed by
AB Diets (Woerden, The Netherlands) and were stored at 4C for a
maximum of 26 weeks. At the age of 6 months the mice were
sacriﬁced via isoﬂurane anaesthesia and heart puncturing.
One mouse in the simvastatin 40 mg/kg BW/day treatment
group rapidly lost weight and was euthanized 2 weeks before the
end of the study. Nevertheless, having completed>90% of the study
period, we decided to include the data from this mouse in all
analyses.
Serum analysis
Blood was collected through a cheek puncture prior to the start
of experimental diet. At end point, blood was collected through a
heart puncture. Blood was stored for 1 h at room temperature,
followed by 30min at 4C, then centrifuged for 5min at 12.000 rpm
and serum was removed and immediately stored at 80C. Total
plasma cholesterol (Roche Diagnostics kit no.1489437) and plasma
triglyceride (Roche diagnostics kit no.1488872) were determined
after defrosting. SAA was also determined in each sample by ELISA
(Tridelta development, Maynooth, Ireland) according to the man-
ufacturer’s instruction. Mouse inﬂammatory cytokines (FGF basic,
GM-CSF, IFN-g, Interleukin (IL)-1a, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-10,
IL-12p40/p70, IL-13, IL-17, IP-10, KC, MCP-1MIG, MIP-1a, TNF-a and
VEGF) were measured using a magnetic 20-plex bead assay (Invi-
trogen, Frederick, MD, USA) according to manufacturer’s
instructions.
Due to technical problems during sample processing, the serum
samples of one mouse in the control group and two of the simva-
statin 40 mg/kg BW/day treatment group were lost.
mCT analysis
The left hind legs of all animals were excised and ﬁxed in 4%
buffered formalin for mCT and histology. We used the Skyscan 1176
X-ray microtomograph and complementary dedicated software
(Bruker micro-CT, Kontich, Belgium) to analyse the subchondral
bone morphology in the proximal tibia of the left knee. The
following scan settings were used: voltage 100 kV; current 100 mA;
ﬁlter 0.5 mm aluminium; image pixel size 17.92 mm; exposure time
2360 ms; frame averaging 3; with 0.4 rotation through 180.
Following scanning, datasets were reconstructed using NRecon
(Bruker-Skyscan). Segmentation was performed with a local
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medial and lateral subchondral bone plate (region of interest
depth: 1.61 mm ventro-dorsal, starting from the anterior inter-
condylar area; region of interest width: adjusted according to total
medio-lateral width in each tibia, then split in half in the middle of
the intercondylar eminence, yielding a lateral and a medial part)
were selected as regions of interest. Finally, CTAnalyser was used to
calculate subchondral bone plate bone volume (BV) and sub-
chondral bone plate thickness, as described previously23.
Histological analysis
After mCT scanning, the legs were decalciﬁed in 10% formic acid
in distilled water for 10 days and embedded in parafﬁn and 6 mm
thick coronal (frontal) histological sections were cut at 100 mm
intervals through the joint. Sections were stained with thionine.
Two independent blinded observers scored cartilage damage at the
medial and lateral sides of both the femur and the tibia according to
the semi-quantitative scoring system devised by the Osteoarthritis
Research Society International (OARSI) histopathology initiative24.
Brieﬂy, this scoring system has a range from 0 to 6, with 0 means
normal cartilage, 1 small ﬁbrillations without loss of cartilage and
3e6 erosions to the calciﬁed cartilage extending from <25% to
>75%. Only slides where all four (i.e., the medial and lateral sides of
both the femur and tibia) locations were visible were used. The
mean score of three different slides was determined and in case of a
>0.5 score discrepancy between the ﬁrst observers, a third inde-
pendent observer rescored the slides. To determine whether
treatment has an effect on synovial inﬂammation, the number of
cell layers of the synovium membrane on the medial side of the
patella was counted. The mean number of cell layers of three
different slides was used in the statistical analysis.
Due to technical error during analysis, the knees of one control
mouse and one combination treated mouse were lost.
Data analysis
Statistical analysis was performed in IBM SPSS statistics 20 (IBM
Corporation, Armonk, New York, USA) and R: A language and
environment for statistical computing 3.0.2 (R Development Core
Team, Vienna, Austria). Data was tested for normality using the
ShapiroeWilk test and for homogeneity of variance using the
Levene’s test. The one way ANOVA with post-hoc Bonferroni
correction was then used for BW at end point, serum total choles-
terol and bone parameters because these parameters were nor-
mally distributed and had homogeneity of variance. For other
serum parameters, food intake and histological data, the Kruskale
Wallis with post-hoc Bonferroni correction was used. The 95%
conﬁdence interval (CI) of the difference between conditions when
the KruskaleWallis test was used, was calculated using the boot-
strap method. To assess the relationship between BW at end point,
serum total cholesterol and mCT data, the Pearson’s correlation
coefﬁcient was used because these parameters were normally
distributed. For all other association analyses, the Spearman’s cor-
relation coefﬁcient was used. P < 0.05 was considered statistically
signiﬁcant.
Results
Simvastatin treatment had no statistically signiﬁcant effect on
serum parameters or OA characteristics
Body weight
As expected, the mean BW of the mice in the control group
increased during the study, reaching a mean of 36.8 (3.2) gramsafter 16weeks (Fig.1). In the simvastatin only treated groups, BWat
end point did not statistically signiﬁcantly differ from control (95%
CI: 3.4 to 4.0 and 2.6 to 4.7 for the difference between control
and 40 or 100 mg/kg BW/day of simvastatin respectively). Food
intake was not statistically signiﬁcantly inﬂuenced by the addition
of simvastatin to the food and the mice received a median of 77% of
the intended dosage of drug (Table I).
Serum markers
No statistical signiﬁcant difference was observed in serum total
cholesterol (95% CI: 0.7 to 0.4 and 0.6 to 0.6), serum total tri-
glyceride (95% CI: 2.4 to 1.1 and 1.0 to 1.6) and SAA levels (95%
CI: 286.4 to 680.1 and 570.0 to 728.4) after both dosages of
simvastatin only treatments (Fig. 2). Using the multiplex assay, IL-
1a, MIP1a and IL-10 were detectable in the serum and compared to
control mice, thesewere not statistically signiﬁcantly different after
simvastatin treatment.
OA cartilage damage
Microscopic evaluation demonstrated variability in cartilage
loss and the amount of subchondral bone in all the groups (Fig. 3).
Cartilage damagewasmost profound in themedial compartment of
the joint. The median OARSI scores in the simvastatin 100 mg/kg
BW/day treated group at the medial femur and tibia were lower
than the untreated control group, although this difference was not
statistically signiﬁcant (95% CI: 0.6 to 3.8 for medial femur
and 1.8 to 4.6 for medial tibia OARSI score). We could not detect a
statistically signiﬁcant reduction of synovial hyperplasia in the
mice after simvastatin treatment compared to controls (95%
CI: 0.7 to 1.0 and 0.7 to 1.0 for the difference between control
and 40 or 100 mg/kg BW/day of simvastatin respectively; Fig. 3).
Twenty one percent of the mice developed patella subluxation
and the prevalence of subluxation was not different between
groups. Excluding the mice with patella dislocation from the ana-
lyses did not alter the results (Supplementary Table I).
mCT analysis
Both the subchondral BV (95% CI:0.1 to 0.1 and0.1 to 0.2) and
plate thickness (95% CI: 40.6 to 42.1 and 24.3 to 60.2) did not
statistically signiﬁcantly differ between mice treated with simva-
statin and control mice (Fig. 4).
Fenoﬁbrate treatment reduced BW, SAA and subchondral bone
Body weight
Mice treatedwith 200mg/kg BW/day fenoﬁbrate had the lowest
mean BW at end point compared to the control group (P < 0.001;
Fig. 1). All fenoﬁbrate treated mice ate more compared to the
control group, although only the fenoﬁbrate 80 mg/kg BW/day
treated group ate statistically signiﬁcantly more (Table I). No signs
of diarrhoea were observed. The mice received a median of 94% of
the intended drug dosage.
Serum markers
We did not detect a statistically signiﬁcant effect of fenoﬁbrate
treatment on serum total triglyceride (95% CI: 0.5 to 2.2 and 0.8
to 2.0 for the difference between control and 80 or 200 mg/kg BW/
day of fenoﬁbrate respectively) and on serum total cholesterol (95%
CI: 0.9 to 0.3 and 0.8 to 0.4; Fig. 2). SAA levels in fenoﬁbrate
treated groups did not change after start of treatment and at end
point were signiﬁcantly lower than in the control group (95% CI: 9.5
to 828.0 and 10.8 to 829). On the multiplex assay only IL-1a, MIP1a
and IL-10 were detectable in the serum (Fig. 2). IL-1a and MIP1a
levels were signiﬁcantly higher in fenoﬁbrate treated mice than in
control mice.
Fig. 1. Effect of treatment on BW and serum metabolic markers. T ¼ 0 weeks represent start of experimental treatment at the age of 8 weeks. Control group received reference diet
for 16 weeks. Treatment groups received simvastatin and/or fenoﬁbrate mixed into their diet for 16 weeks. Indicated dosages are intended drug intake/kg BW/day. Combination
group received simvastatin 40 mg and fenoﬁbrate 80 mg. (A) Body weight, (B) Serum triglyceride, (C) Serum total cholesterol. Values indicate mean þ SD (n ¼ 11e12 mice per
group). Horizontal dashed line: mean value of T ¼ 0. * ¼ P < 0.01 vs Control group. ** ¼ P < 0.001 vs Control group.
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We could not detect a statistically signiﬁcant reduction of
medial femur (95% CI: 2.8 to 3.4 and 3.5 to 2.6) and tibia (95%
CI: 4.3 to 4.6 and 3.4 to 4.3) OARSI scores and synovial hyper-
plasia (95% CI: 1.7 to 1.8 and0.6 to 1.3) in the fenoﬁbrate treated
mice compared to controls (Fig. 3).mCT analysis
Mice treated with 200 mg/kg BW/day fenoﬁbrate had a lower
subchondral BV and plate thickness than the control group
although only the lower subchondral BVwas statistically signiﬁcant
(Fig. 4).Table I
Total food intake and drug intake per mouse*
Treatment group
(intended drug
intake)
Average total food
intake per mouse
in gramsy
P value Actual drug intake per
kg BW per day in mg
(% of intended drug
intake)
Control 492.1  15.7
Simvastatin 40 mg 467.1  13.8 1.000 30.7  1.8 (77)
Simvastatin 100 mg 460.2  4.2 0.265 76.2  2.6 (76)
Fenoﬁbrate 80 mg 557.5  18.8 0.009 74.5  2.0 (93)
Fenoﬁbrate 200 mg 524.9  8.6 0.265 189.3  5.5 (95)
Combination 484.3  11.8 1.000 33.5  1.4 (84)z
67.0  2.8 (84)x
* Treatment groups received simvastatin and/or fenoﬁbrate mixed with their diet
for 16 weeks. Indicated dosages are intended drug intake/kg BW/day. Combination
group received simvastatin 40 mg and fenoﬁbrate 80 mg. Data are mean  SD;
KruskaleWallis test with post-hoc Bonferroni correction was performed; P values
indicate the statistical difference between treatment and control group.
y Average total food intake per mouse for 16 weeks.
z Simvastatin 40 mg.
x Fenoﬁbrate 80 mg.Effects of combination treatment of simvastatin and fenoﬁbrate
The mean BW of the mice treated with a combination of sim-
vastatin and fenoﬁbrate at the end of the study was lower than the
mean BW in the control group (P ¼ 0.003, Fig. 1). The mice received
84% of the intended dosage simvastatin and fenoﬁbrate (Table I).
Only SAA was statistically signiﬁcantly different between mice
treated with a combination of simvastatin and fenoﬁbrate and
controls (Figs. 2e4).Correlation between BW, serum markers, cartilage damage, synovial
hyperplasia and bone changes
BW at end point correlated with serum total triglyceride
(P < 0.001), IL-1a (P < 0.001) and MIP1a (P ¼ 0.001) and sub-
chondral BV (P ¼ 0.01). In none of the treatment groups, serum
inﬂammation markers correlated statistically signiﬁcantly with OA
cartilage damage (Table II). SAA levels did not differ between mice
with and without cartilage damage. SAA levels correlated to sub-
chondral BV (P ¼ 0.008) Both subchondral BV (P ¼ 0.002), plate
thickness (P < 0.001) and synovial hyperplasia (P < 0.001) corre-
lated with cartilage damage (Table II).Discussion
In this study we investigated whether drugs often used to
reduce the morbidity and mortality of metabolic syndrome and
obesity could serve as a therapy to prevent or treat OA. We did not
ﬁnd a statistically signiﬁcantly reduction of the severity of cartilage
damage in STR/Ort mice with neither simvastatin, fenoﬁbrate nor
Fig. 2. Effect of simvastatin and/or fenoﬁbrate on serum inﬂammatory markers. Control group received reference diet. Treatment groups received simvastatin and/or fenoﬁbrate
mixed with their diet for 16 weeks. Indicated dosages are intended drug intake/kg BW/day. Combination group received simvastatin 40 mg and fenoﬁbrate 80 mg. (A) Serum IL-1a,
(B) Serum MIP1a, (C) Serum IL-10 and (D) SAA levels. T ¼ 0: values before treatment at the age of 8 weeks. Horizontal dashed line indicates the mean value at the start of treatment
(T ¼ 0). Values indicate mean þ SD (n ¼ 11e12 mice per group).
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vented a high subchondral BV.
The STR/Ort strain was carefully chosen for this study because
these mice have been described to develop OA and metabolic
syndrome spontaneously at a relatively young age19, thus resem-
bling patients with metabolic OA4. Since statins and ﬁbrates are
used to improve the metabolic proﬁle of patients, the use of this
strain seemed to match the subgroup of metabolic OA patients that
could beneﬁt from treatment with these drugs. In addition to
hyperlipidaemia and obesity, other possible causes for OA predis-
position in the STR/Ort strain have been discussed, such as the role
of patella subluxation18,25. When patella subluxation occurs, it is a
major biomechanical risk factor and disease modifying effects of
simvastatin or fenoﬁbrate would be highly unlikely. In our study,
patella subluxation occurred in 21% of the mice throughout all the
groups. Although all mice with patella subluxation had extensive
cartilage damage, not all mice with extensive cartilage damage had
patella subluxation. This suggests that patella subluxation is not the
main cause of OA in these mice and is not likely to mask the effects
of simvastatin or fenoﬁbrate.
In a previous human cohort study we found that statin use was
associated with a lower incidence and reduced progression of knee
OA on X-rays15. In an other study statin use was associated with
lower incidence of clinical OA16. In the present study with STR/Ort
mice, simvastatin didnot lower the serumtotal cholesterol level. This
could be explained by a different cholesterolmetabolism pathway in
mice than in humans26e28. The absence of a statistically signiﬁcant
effect of simvastatin on OA in our study could indicate that choles-
terol and OA might be linked to each other and that lowering
cholesterol by statins is important to reduce OA development.Furthermore, different types of statins were included in the human
clinical studies. These different types of statins have been described
to have different therapeutic effects29. The serum levels of total
cholesterol in the control mice in our study were comparable to a
previous study19. Serum cholesterol can be increased with a high fat
diet in mice and decreases after treatment with statin30,31. In addi-
tion, we have previously reported that statin treatment decreased
thedevelopment of OA inmice on a high fat diet32. This suggests that
the effect of statin treatment could also depend on the type of diet.
However, this conclusion should be drawnwith caution, because the
studies of Fraulob31 and Gierman32 used rosuvastatin and the study
of Paraskevast30 atorvastatin, whereaswe administered simvastatin.
Aswith humans, these different types of statins have been described
to have different therapeutic effects in mice21.
The result of our study that simvastatin could not statistically
signiﬁcantly reduce OA cartilage damage is also not consistent with
a previous study by Yudoh et al.14, who reported a statistically
signiﬁcant decrease in OA cartilage score in STR/Ort mice after 12
and 24 weeks of simvastatin (40 mg/kg BW/day) treatment. This
inconsistency could be due to differences in strains: Yudoh and
colleagues used STR/OrtCrlj mice obtained from Charles River Japan
whereas we used STR/OrtOlaHsd mice obtained from Harlan, Italy.
Response to simvastatin could have been different between these
two populations of mice. Furthermore, in the study by Yudoh et al.,
the cartilage damage in the untreated group at the age of 24 weeks
was less severe than in the control group in our study. This in-
dicates that simvastatin might be more effective in slowly devel-
oping or less severe OA. Lastly, Yudoh et al. administrated the drugs
by daily gavage instead of mixing it with the food and therefore a
different therapeutic level might be reached in the mice.
Fig. 3. Histological analysis of effect of simvastatin and/or fenoﬁbrate treatment on cartilage damage in STR/Ort mice. The coronal sections of cartilage in the weight-bearing area of
the tibiofemoral compartment of the left knee were stained with thionine and severity of cartilage damage was scored on a scale of 0e6 using the OARSI histological scoring scale.
Control group received reference diet for 16 weeks. Treatment groups received simvastatin and/or fenoﬁbrate mixed with their diet for 16 weeks. Indicated dosages are intended
drug intake/kg BW/day. Combination group received simvastatin 40 mg and fenoﬁbrate 80 mg. (A) Representative picture of score 0: normal cartilage (B) Representative picture of
score 6: Vertical clefs/erosion to the calciﬁed cartilage extending to >75% of the surface. Pictures are taken at 40 magniﬁcation. (C) Quantiﬁcation of OARSI scores of the medial
femur. (D) Quantiﬁcation of OARSI scores of the medial tibia. (E) Number of cell layers in the synovial membrane. Each dot represents an individual mouse (n ¼ 11e12 mice per
group) Horizontal line indicates median value per group in C and D. Mean  SD is shown in E.
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serum lipids in patients with hypertriglyceridemia. Serum triglyc-
eridewas not lowered after treatment with fenoﬁbrate in our study,
but the treated mice gained less weight. BW was however
moderately correlated to serum triglyceride suggesting that weight
reduction could reduce serum triglyceride. Control mice continued
to gain BWover time, reaching a meanweight of 36.8  3.2 g at the
age of 24 weeks. This is comparable to previous studies19,33. The
reduction in BW gain by fenoﬁbrate treatment however, did not
protect the mice from developing cartilage damage. This absence of
correlation between BW and incidence of cartilage damage con-
ﬁrms our earlier ﬁndings32 that obesity does not increase OA
cartilage damage by biomechanical overloading.
In our study, serum cholesterol and serum triglyceride were
both not correlated with cartilage damage. This suggests that in theSTR/Ort mice lipid metabolism is not the primary cause of spon-
taneous OA cartilage damage development. Next to their effect on
lipid metabolism, statins and ﬁbrates are known to have an effect
on inﬂammation8,9,11e13. SAA, a marker for systemic inﬂammation,
increased in control mice with ageing. SAA has been associated
with inﬂammatory processes in atherosclerosis and rheumatoid
arthritis34e36, is increased in obesity37 and clinical studies have
shown that SAA can be lowered by fenoﬁbrate and simvastatin
treatment38e40. In the present study with STR/Ort mice, SAA levels
were only lowered after fenoﬁbrate treatment. SAA is described to
be induced by the cytokines IL-1b, IL-6 and TNF-a and it can acti-
vate the NF-kB pathway34,35,41. Kyostio-Moore et al.42 reported
elevated inﬂammatory cytokines in the serum of STR/Ort mice
including IL-1b, IL-12p70 and IL-5, and these changes were corre-
lated with cartilage damage. We were able to detect IL-1a, MIP1a
Fig. 4. Effect of simvastatin and/or fenoﬁbrate treatment on subchondral bone plate BV
and thickness of the tibia plateau in STR/Ort mice. Control group received reference
diet for 16 weeks. Treatment groups received simvastatin and/or fenoﬁbrate mixed
with their diet for 16 weeks. Indicated dosages are intended drug intake/kg BW/day.
Combination group received simvastatin 40 mg and fenoﬁbrate 80 mg. (A) Sub-
chondral bone plate BV (B) Subchondral bone plate thickness, Values indicate
mean þ SD (n ¼ 11e12 mice per group).
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detected. Surprisingly, IL-1a, and MIP1a levels were signiﬁcantly
higher in mice that received fenoﬁbrate treatment. This suggests
that different aspects of inﬂammation might occur that possibly
counteract each other. Furthermore, we found no correlationTable II
Correlation between BW, serum markers, OARSI cartilage scores, synovial hyperplasia an
BW (end point) OARSI score
Total Femur
BW (end point) 0.14 0.04
Serum
Total cholesterol 0.09 0.07 0.02
Total triglyceride 0.45 0.12 0.10
Amyloid A 0.21 0.01 0.08
IL-1a 0.52 0.07 0.09
MIP1a 0.44 0.09 0.13
IL-10 0.11 0.08 0.14
Synovium cell layers 0.33 0.62
Subchondral bone plate volume 0.31
Subchondral bone plate thickness 0.22
Serummarkers weremeasured at end point after 16weeks of treatment; OARSI scores for
point, serum total cholesterol and mCT data were calculated using the Pearson correlatio
Spearman correlation coefﬁcient; Signiﬁcant correlations (P < 0.05) are shown in bold.between individual serum inﬂammatory markers and synovial
hyperplasia, suggesting that systemic inﬂammation is not directly
related to local inﬂammatory changes in the knee in our STR/Ort
mice.
Fenoﬁbrate lowers lipid levels by activating PPARa. It has been
suggested that STR/Ort mice have reduced endogenous PPARa
signalling. This reduction of PPARa signalling could be associated
with increased osteogenic differentiation and reduced adipogenic
and chondrogenic differentiation of bone marrow derived mesen-
chymal stem cells and thus be associated with the development of
OA in these mice20. In our study, PPARa activation with 200 mg/kg
BW/day fenoﬁbrate did indeed reduce the total BV in the sub-
chondral bone. We could however, not detect a signiﬁcant reduc-
tion of cartilage damage in our study. Changes in cartilage and
subchondral bone during OA development are thought to be
correlated to each other43 and we did ﬁnd a moderate correlation
between cartilage damage and subchondral bone parameters. The
absence of a statistically signiﬁcant reduction of cartilage damage
might be due to the limited sensitivity of the histological cartilage
damage scoring or to the high variation in incidence of spontaneous
OA cartilage damage in these mice. In the present study, 60% of the
animals had developed OA cartilage damage at 24 weeks of age,
which is less than the 80% reported in other studies that we used
for our power calculation18. Moreover, sincewe used a spontaneous
model of OA development, individual mice developed OA at a
different speed25 which might explain the large variation in carti-
lage damage in the control group.
Alternatively, it is possible that themice treatedwith fenoﬁbrate
are at a different phase in OA development. During OA develop-
ment in mice, a biphasic subchondral bone turnover process is
taking place, with initial loss of subchondral bone, followed by
increased volume and thickening of the subchondral bone
plate23,44. In the fenoﬁbrate treated mice, initial OA development
could have been delayed as demonstrated by the lower sub-
chondral BV whereas the other mice already progressed to a
thickening of the subchondral plate. Further investigation with
time series is needed to conﬁrm this hypothesis.
Possible side effects of statins and fenoﬁbrates are muscle pain
and elevated liver enzymes. Furthermore, toxicology studies per-
formed onmice showed that administration of very high dosages of
simvastatin or fenoﬁbrate for 72 weeks could possibly induce liver
carcinomas45,46. In our study, we did not analyse the livers of our
mice at age 20 weeks for the presence of liver carcinomas, so we
cannot exclude the presence of these tumours. We included one
group of mice that was treated with a combination of simvastatin
and fenoﬁbrate. This combination has been shown in clinical
studies to be more effective in decreasing cardiovasculard mCT data
Synovium
cell layers
Subchondral bone
plate volume
Subchondral bone
plate volume
Tibia
0.19 0.32 0.31 0.22
0.05 0.04 0.26 0.23
0.10 0.28 0.03 0.04
0.08 0.12 0.34 0.19
0.04 0.09 0.09 0.13
0.02 0.05 0.01 0.06
0.03 0.01 0.01 0.11
0.32 0.42
0.37
0.49
the total joint, both femur and tibial compartments; Correlations between BWat end
n coefﬁcient; Correlations between all other parameters were calculated using the
W. Wei et al. / Osteoarthritis and Cartilage 22 (2014) 293e301300mortality47, treating dyslipidemia48 and decreasing inﬂammation49
compared to monotherapy. Because the combination is demon-
strated to be more effective47e49, a lower dose of both drugs can be
used and therefore less side effects will occur50. Unfortunately, we
did not see synergistic effects of the combination treatment in our
study. Simvastatin and fenoﬁbrate are both metabolised in the liver
and thereby lowering the levels that are reached locally in the knee
or subchondral bone. Methods to increase the levels of both drugs
locally, such as intra-articularly or subcutaneously injections might
provide options to increase the local effects and reduce the sys-
temic side effects.
In summary, we could not detect a statistically signiﬁcantly
decrease of simvastatin or fenoﬁbrate treatment on the develop-
ment of cartilage damage in 6 months old STR/Ort mice. On the
other hand, the effect of fenoﬁbrate on subchondral bone
morphology and the correlation between subchondral bone
morphology and cartilage damage suggests there might be a mild
effect on OA development that is masked by the insensitivity of the
cartilage score or the high variation in cartilage damage inmice of 6
months old. Furthermore, our data suggest that biomechanical
changes due to overweight or patella subluxation and spontaneous
metabolic changes are not the primary cause of OA in the STR/Ort
mouse. Complex inﬂammatory processes occur in these mice that
did not affect the cartilage directly.
Nonetheless, we do not exclude that lipid lowering drugs can
still be beneﬁcial in other subtypes of OA such as high fat diet
induced metabolic OA as indicated by our previous studies. This
emphasizes the importance of further subtyping OA to ﬁnd possi-
bilities for pharmacological treatment of OA.
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